UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D. C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 25, 2004
HEMACARE CORPORATION
(Exact name of registrant as specified in its charter)
CALIFORNIA 000-15223 95-3280412
(State or other (Commission File No.) (I.R.S. employer
jurisdiction of Identification No.)
organization or
incorporation)
21101 Oxnard Street
Woodland Hills, CA 91367
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (818) 226-1968
Item 7. Financial Statements and Exhibits.
(c) Exhibits
Exhibit Number Description
-------------- -----------------------------------------------
99.1 Press Release issued by HemaCare Corporation,
dated March 25, 2004
99.2 Transcript of the presentations given by Judi
Irving, CEO, and Robert S. Chilton, CFO, at a
conference call conducted by HemaCare Corporation
on March 25, 2004
Item 12 Results of Operations and Financial COndition
On March 25, 2004, HemaCare Corporation issued a press release
announcing the financial results for the year ended December 31, 2003.
A copy is attached as Exhibit 99.1 to this report and is
incorporated herein by this reference.
Additionally, on March 25, 2004, HemaCare Corporation held an investor
conference call discussing the financial results for the year ended
December 31, 2003. A transcript of the presentations given by
Judi Irving, CEO, and Robert S. Chilton, CFO, in the call is
attached to this report as Exhibit 99.2 and is incorporated
herein by this reference.
The information in this Current Report on Form 8-K, including
the exhibits, will not be treated as "filed" for the purposes of
Section 18 of the Securities and Exchange Act of 1934 (the
"Exchange Act") or otherwise subject to the liabilities of that
section. This information will not be incorporated by reference
into a filing under the Securities Act of 1933, or into another
filing under the Exchange Act, unless that filing expressly
refers to specific information in this report.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
Date: March 25, 2004 HEMACARE CORPORATION
/s/ Robert S. Chilton
-------------------------
Robert S. Chilton
Chief Financial Officer
EXHIBIT INDEX
Exhibit Number Description
-------------- -----------------------------------------------
99.1 Press Release issued by HemaCare, Corporation
dated March 25, 2004
99.2 Transcript of the presentations given by Judi Irving,
CEO, and Robert S. Chilton, CFO, at a conference
call conducted by HemaCare Corporation on March
25, 2004